JP2020513829A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020513829A5 JP2020513829A5 JP2019552109A JP2019552109A JP2020513829A5 JP 2020513829 A5 JP2020513829 A5 JP 2020513829A5 JP 2019552109 A JP2019552109 A JP 2019552109A JP 2019552109 A JP2019552109 A JP 2019552109A JP 2020513829 A5 JP2020513829 A5 JP 2020513829A5
- Authority
- JP
- Japan
- Prior art keywords
- vector
- domain
- cell
- group
- tcr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100019461 CD28 Human genes 0.000 claims 7
- 101700033362 CD28 Proteins 0.000 claims 7
- 108091008153 T cell receptors Proteins 0.000 claims 7
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 7
- 210000004027 cells Anatomy 0.000 claims 6
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- -1 CD3 epsilon Proteins 0.000 claims 4
- 102100005828 CD5 Human genes 0.000 claims 4
- 101700066525 CD5 Proteins 0.000 claims 4
- 102100001475 ITGB2 Human genes 0.000 claims 4
- 101710040448 TNFRSF4 Proteins 0.000 claims 4
- 102100013135 TNFRSF4 Human genes 0.000 claims 4
- 102100009537 TNFRSF9 Human genes 0.000 claims 4
- 101710040535 TNFRSF9 Proteins 0.000 claims 4
- 230000011664 signaling Effects 0.000 claims 4
- 102100008191 CD8A Human genes 0.000 claims 3
- 101700054655 CD8A Proteins 0.000 claims 3
- 206010024324 Leukaemias Diseases 0.000 claims 3
- 102000001555 Sialic Acid Binding Ig-like Lectin 3 Human genes 0.000 claims 3
- 108010029180 Sialic Acid Binding Ig-like Lectin 3 Proteins 0.000 claims 3
- 230000004068 intracellular signaling Effects 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 206010000880 Acute myeloid leukaemia Diseases 0.000 claims 2
- 102100000189 CD22 Human genes 0.000 claims 2
- 101700020617 CD22 Proteins 0.000 claims 2
- 102100019459 CD27 Human genes 0.000 claims 2
- 101700056583 CD27 Proteins 0.000 claims 2
- 102100016493 CD33 Human genes 0.000 claims 2
- 101700017647 CD33 Proteins 0.000 claims 2
- 102100016530 CD37 Human genes 0.000 claims 2
- 101700044364 CD37 Proteins 0.000 claims 2
- 102100013077 CD4 Human genes 0.000 claims 2
- 101700022938 CD4 Proteins 0.000 claims 2
- 102100005830 CD70 Human genes 0.000 claims 2
- 101700017377 CD70 Proteins 0.000 claims 2
- 102100019451 CD80 Human genes 0.000 claims 2
- 101700080477 CD80 Proteins 0.000 claims 2
- 102100016531 CD9 Human genes 0.000 claims 2
- 101700017162 CD9 Proteins 0.000 claims 2
- 206010008958 Chronic lymphocytic leukaemia Diseases 0.000 claims 2
- 102100015540 FCGR1A Human genes 0.000 claims 2
- 101710003440 FCGR1A Proteins 0.000 claims 2
- 102100015541 FCGR3A Human genes 0.000 claims 2
- 101710044656 FCGR3A Proteins 0.000 claims 2
- 101710044657 FCGR3B Proteins 0.000 claims 2
- 102100004898 HCST Human genes 0.000 claims 2
- 101700079958 HCST Proteins 0.000 claims 2
- 102100004115 ICAM1 Human genes 0.000 claims 2
- 102100019442 ITGAL Human genes 0.000 claims 2
- 101710006573 ITGAL Proteins 0.000 claims 2
- 101710006663 ITGB2 Proteins 0.000 claims 2
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 claims 2
- 208000000429 Leukemia, Lymphocytic, Chronic, B-Cell Diseases 0.000 claims 2
- 208000008456 Leukemia, Myelogenous, Chronic, BCR-ABL Positive Diseases 0.000 claims 2
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 claims 2
- 108010064548 Lymphocyte Function-Associated Antigen-1 Proteins 0.000 claims 2
- 229920001850 Nucleic acid sequence Polymers 0.000 claims 2
- 102100005499 PTPRC Human genes 0.000 claims 2
- 101700059076 PTPRC Proteins 0.000 claims 2
- 210000001744 T-Lymphocytes Anatomy 0.000 claims 2
- 102100008188 TYROBP Human genes 0.000 claims 2
- 108060008723 TYROBP Proteins 0.000 claims 2
- 230000001154 acute Effects 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000038129 antigens Human genes 0.000 claims 2
- 108091007172 antigens Proteins 0.000 claims 2
- 201000006934 chronic myeloid leukemia Diseases 0.000 claims 2
- 230000000139 costimulatory Effects 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 229920000160 (ribonucleotides)n+m Polymers 0.000 claims 1
- 208000004736 B-Cell Leukemia Diseases 0.000 claims 1
- 210000004443 Dendritic Cells Anatomy 0.000 claims 1
- 241000713666 Lentivirus Species 0.000 claims 1
- 241000712079 Measles morbillivirus Species 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000009052 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 1
- 208000000389 T-Cell Leukemia Diseases 0.000 claims 1
- 101710038571 TNFRSF19 Proteins 0.000 claims 1
- 102100003097 TNFRSF19 Human genes 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000000259 anti-tumor Effects 0.000 claims 1
- 229920003013 deoxyribonucleic acid Polymers 0.000 claims 1
- 230000003834 intracellular Effects 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 241001529453 unidentified herpesvirus Species 0.000 claims 1
- 241001430294 unidentified retrovirus Species 0.000 claims 1
Claims (10)
- N末端からC末端に、
(i)配列番号1、3、5、7、9、または11を含むヌクレオチド配列によりコードされるCD33抗原結合性ドメインを含む少なくとも1つの細胞外抗原結合性ドメイン、
(ii)T細胞受容体(TCR)のアルファ鎖、TCRのベータ鎖、TCRのゼータ鎖、CD28、CD3イプシロン、CD45、CD4、CD5、CD8、CD9、CD16、CD22、CD33、CD37、CD64、CD80、CD86、CD134、CD137およびCD154またはそれらのいずれかの組み合わせからなる群から選択されたタンパク質の膜貫通ドメイン、
(iii)OX40、CD70、CD27、CD28、CD5、ICAM−1、LFA−1(CD11a/CD18)、ICOS(CD278)、DAP10、DAP12および4−1BB(CD137)またはそれらのいずれかの組み合わせからなる群から選択された機能的シグナル伝達ドメインを含む少なくとも1つの共刺激ドメイン、ならびに、
(iv)4−1BB(CD137)、CD28およびCD3ゼータシグナル伝達ドメインまたはそれらのいずれかの組み合わせからなる群から選択された細胞内シグナル伝達ドメイン
を含む、キメラ抗原受容体(CAR)をコードする、単離された核酸分子。 - 請求項1に記載の核酸分子を含むベクター。
- DNAベクター、RNAベクター、プラスミドベクター、コスミドベクター、ヘルペスウイルスベクター、麻疹ウイルスベクター、レンチウイルスベクター、アデノウイルスベクター、またはレトロウイルスベクター、またはそれらの組合せからなる群から選択される、請求項2に記載のベクター。
- 請求項2に記載のベクターを含む細胞。
- 請求項2のベクターを含む抗腫瘍有効量のヒトT細胞集団を含む医薬組成物であって、前記T細胞ががんを有するヒトのT細胞であり、前記がんが白血病である、医薬組成物。
- それを必要とする対象におけるがんを処置するための医薬組成物を製造するためのT細胞集団の使用であって、ここにおいてT細胞はキメラ抗原受容体(CAR)をコードする核酸配列を含み、ここにおいてCARは、N末端からC末端に、
(i)配列番号2、4、6、8、10および12からなる群から選択されたアミノ酸配列を含むCD33抗原結合性ドメインを含む少なくとも1つの細胞外抗原結合性ドメイン、
(ii)TCRのアルファ鎖、TCRのベータ鎖、TCRのゼータ鎖、CD28、CD3イプシロン、CD45、CD4、CD5、CD8、CD9、CD16、CD22、CD33、CD37、CD64、CD80、CD86、CD134、CD137およびCD154またはそれらのいずれかの組み合わせからなる群から選択されたタンパク質の膜貫通ドメイン、
(iii)OX40、CD70、CD27、CD28、CD5、ICAM−1、LFA−1(CD11a/CD18)、ICOS(CD278)、DAP10、DAP12および4−1BB(CD137)またはそれらのいずれかの組み合わせからなる群から選択された機能的シグナル伝達ドメインを含む少なくとも1つの共刺激ドメイン、ならびに、
(iv)4−1BB(CD137)、CD28およびCD3ゼータシグナル伝達ドメインまたはそれらのいずれかの組み合わせからなる群から選択された細胞内シグナル伝達ドメイン
を含み、ここにおいて、前記T細胞ががんを有する対象のT細胞であり、前記がんが白血病である、使用。 - コードされる前記CD33抗原結合性ドメインが、リンカーまたはスペーサードメインによって膜貫通ドメインに接続されている、請求項6に記載の使用。
- コードされる前記リンカーまたはスペーサードメインが、CD8、TNFRSF19、またはCD28の細胞外ドメインに由来する、請求項7に記載の使用。
- コードされる前記細胞内シグナル伝達ドメインが、CD3ゼータ細胞内ドメインを含む、請求項6に記載の使用。
- 前記白血病が、急性骨髄性白血病(AML)、芽球性形質細胞様樹状細胞腫瘍(BPDCN)、慢性骨髄性白血病(CML)、慢性リンパ性白血病(CLL)、急性リンパ芽球性T細胞白血病(T−ALL)、または急性リンパ芽球性B細胞白血病(B−ALL)である、請求項6に記載の使用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2022139092A JP7448896B2 (ja) | 2017-03-24 | 2022-09-01 | 抗cd33免疫療法によりがんを処置するための組成物および方法 |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762476438P | 2017-03-24 | 2017-03-24 | |
US62/476,438 | 2017-03-24 | ||
US201862620139P | 2018-01-22 | 2018-01-22 | |
US62/620,139 | 2018-01-22 | ||
PCT/US2018/024183 WO2018175988A1 (en) | 2017-03-24 | 2018-03-23 | Compositions and methods for treating cancer with anti-cd33 immunotherapy |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022139092A Division JP7448896B2 (ja) | 2017-03-24 | 2022-09-01 | 抗cd33免疫療法によりがんを処置するための組成物および方法 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2020513829A JP2020513829A (ja) | 2020-05-21 |
JP2020513829A5 true JP2020513829A5 (ja) | 2021-03-11 |
JP7137896B2 JP7137896B2 (ja) | 2022-09-15 |
Family
ID=62090025
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019552109A Active JP7137896B2 (ja) | 2017-03-24 | 2018-03-23 | 抗cd33免疫療法によりがんを処置するための組成物および方法 |
JP2022139092A Active JP7448896B2 (ja) | 2017-03-24 | 2022-09-01 | 抗cd33免疫療法によりがんを処置するための組成物および方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022139092A Active JP7448896B2 (ja) | 2017-03-24 | 2022-09-01 | 抗cd33免疫療法によりがんを処置するための組成物および方法 |
Country Status (7)
Country | Link |
---|---|
US (3) | US10426797B2 (ja) |
EP (1) | EP3601356A1 (ja) |
JP (2) | JP7137896B2 (ja) |
CN (2) | CN112695050A (ja) |
AU (1) | AU2018240556A1 (ja) |
CA (1) | CA3057838A1 (ja) |
WO (1) | WO2018175988A1 (ja) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3184548A1 (en) | 2015-12-23 | 2017-06-28 | Miltenyi Biotec GmbH | Chimeric antigen receptor with cytokine receptor activating or blocking domain |
JP7160482B2 (ja) | 2016-09-02 | 2022-10-25 | レンティジェン・テクノロジー・インコーポレイテッド | Duocarを用いてがんを処置するための組成物および方法 |
CA3052779A1 (en) | 2017-02-17 | 2018-08-23 | Fred Hutchinson Cancer Research Center | Combination therapies for treatment of bcma-related cancers and autoimmune disorders |
JP7137896B2 (ja) | 2017-03-24 | 2022-09-15 | レンティジェン・テクノロジー・インコーポレイテッド | 抗cd33免疫療法によりがんを処置するための組成物および方法 |
KR20200116077A (ko) | 2017-11-01 | 2020-10-08 | 주노 쎄러퓨티크스 인코퍼레이티드 | B 세포 성숙 항원에 특이적인 키메라 항원 수용체 및 암호화 폴리뉴클레오타이드 |
WO2020092848A2 (en) * | 2018-11-01 | 2020-05-07 | Juno Therapeutics, Inc. | Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen |
EP3876961A4 (en) * | 2018-11-06 | 2023-01-25 | Washington University | CHIMERIC ANTIGEN RECEPTOR MEMORY-LIKE (CARML) NK CELLS AND METHODS FOR THEIR PRODUCTION AND USE |
CA3125033A1 (en) * | 2019-01-22 | 2020-07-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | High affinity monoclonal antibodies targeting glypican-1 and methods of use |
SG11202111890RA (en) * | 2019-05-08 | 2021-11-29 | Inhibrx Inc | Cd33 targeted immunotherapies |
CN113150167A (zh) * | 2020-01-22 | 2021-07-23 | 中国人民解放军总医院第五医学中心 | 一种能够反转pd-1免疫抑制信号的car t细胞结构em1设计 |
CN111848819A (zh) * | 2020-07-31 | 2020-10-30 | 广东昭泰体内生物医药科技有限公司 | 一种靶向msln的嵌合抗原受体及其应用 |
WO2023086829A1 (en) * | 2021-11-09 | 2023-05-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Igg4 hinge-containing chimeric antigen receptors targeting glypican-3 (gpc3) and use thereof |
CN114133457B (zh) * | 2021-12-08 | 2022-08-19 | 郑州源创吉因实业有限公司 | 一种靶向ror1和cd33的双特异性嵌合抗原受体(car)及其应用 |
WO2024026107A2 (en) | 2022-07-28 | 2024-02-01 | Lentigen Technology, Inc. | Chimeric antigen receptor therapies for treating solid tumors |
WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
US20240075142A1 (en) | 2022-08-26 | 2024-03-07 | Lentigen Technology, Inc. | Compositions and Methods for Treating Cancer with Fully Human Anti-CD20/CD19 Immunotherapy |
Family Cites Families (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3060165A (en) | 1962-10-23 | Preparation of toxic ricin | ||
US3896111A (en) | 1973-02-20 | 1975-07-22 | Research Corp | Ansa macrolides |
US4151042A (en) | 1977-03-31 | 1979-04-24 | Takeda Chemical Industries, Ltd. | Method for producing maytansinol and its derivatives |
US4137230A (en) | 1977-11-14 | 1979-01-30 | Takeda Chemical Industries, Ltd. | Method for the production of maytansinoids |
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4265814A (en) | 1978-03-24 | 1981-05-05 | Takeda Chemical Industries | Matansinol 3-n-hexadecanoate |
US4307016A (en) | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
JPS5562090A (en) | 1978-10-27 | 1980-05-10 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
US4256746A (en) | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
JPS55164687A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS5566585A (en) | 1978-11-14 | 1980-05-20 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS55102583A (en) | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
JPS55162791A (en) | 1979-06-05 | 1980-12-18 | Takeda Chem Ind Ltd | Antibiotic c-15003pnd and its preparation |
JPS55164685A (en) | 1979-06-08 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS55164686A (en) | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
US4309428A (en) | 1979-07-30 | 1982-01-05 | Takeda Chemical Industries, Ltd. | Maytansinoids |
JPS5645483A (en) | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
JPS5645485A (en) | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
EP0028683A1 (en) | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotic C-15003 PHO and production thereof |
WO1982001188A1 (en) | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | 4,5-deoxymaytansinoide compounds and process for preparing same |
US4450254A (en) | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
US4315929A (en) | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
US4313946A (en) | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
JPS57192389A (en) | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US4486414A (en) | 1983-03-21 | 1984-12-04 | Arizona Board Of Reagents | Dolastatins A and B cell growth inhibitory substances |
US4957735A (en) | 1984-06-12 | 1990-09-18 | The University Of Tennessee Research Corporation | Target-sensitive immunoliposomes- preparation and characterization |
US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
US5079163A (en) | 1985-03-29 | 1992-01-07 | Cetus Corporation | Recombinant ricin toxin fragments |
US4689401A (en) | 1986-03-06 | 1987-08-25 | Cetus Corporation | Method of recovering microbially produced recombinant ricin toxin a chain |
US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
US4902505A (en) | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US4816444A (en) | 1987-07-10 | 1989-03-28 | Arizona Board Of Regents, Arizona State University | Cell growth inhibitory substance |
US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
US5208021A (en) | 1987-10-05 | 1993-05-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Method of preparing diphtheria immunotoxins |
US5792458A (en) | 1987-10-05 | 1998-08-11 | The United States Of America As Represented By The Department Of Health And Human Services | Mutant diphtheria toxin conjugates |
IL106992A (en) | 1988-02-11 | 1994-06-24 | Bristol Myers Squibb Co | Noble hydrazonic history of anthracycline and methods for their preparation |
US5076973A (en) | 1988-10-24 | 1991-12-31 | Arizona Board Of Regents | Synthesis of dolastatin 3 |
US4978744A (en) | 1989-01-27 | 1990-12-18 | Arizona Board Of Regents | Synthesis of dolastatin 10 |
US5055303A (en) | 1989-01-31 | 1991-10-08 | Kv Pharmaceutical Company | Solid controlled release bioadherent emulsions |
US4879278A (en) | 1989-05-16 | 1989-11-07 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15 |
US4986988A (en) | 1989-05-18 | 1991-01-22 | Arizona Board Of Regents | Isolation and structural elucidation of the cytostatic linear depsipeptides dolastatin 13 and dehydrodolastatin 13 |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5271961A (en) | 1989-11-06 | 1993-12-21 | Alkermes Controlled Therapeutics, Inc. | Method for producing protein microspheres |
US5188837A (en) | 1989-11-13 | 1993-02-23 | Nova Pharmaceutical Corporation | Lipsopheres for controlled delivery of substances |
US5138036A (en) | 1989-11-13 | 1992-08-11 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Isolation and structural elucidation of the cytostatic cyclodepsipeptide dolastatin 14 |
US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
JP3266311B2 (ja) | 1991-05-02 | 2002-03-18 | 生化学工業株式会社 | 新規ポリペプチドおよびこれを用いる抗hiv剤 |
US5254342A (en) | 1991-09-30 | 1993-10-19 | University Of Southern California | Compositions and methods for enhanced transepithelial and transendothelial transport or active agents |
US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
DE69311538D1 (de) | 1992-03-12 | 1997-07-17 | Alkermes Inc | Acth enthaltende mikrokugeln mit gesteuerter abgabe |
US5534496A (en) | 1992-07-07 | 1996-07-09 | University Of Southern California | Methods and compositions to enhance epithelial drug transport |
US6034065A (en) | 1992-12-03 | 2000-03-07 | Arizona Board Of Regents | Elucidation and synthesis of antineoplastic tetrapeptide phenethylamides of dolastatin 10 |
US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
US5410024A (en) | 1993-01-21 | 1995-04-25 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide amides |
US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
US5514670A (en) | 1993-08-13 | 1996-05-07 | Pharmos Corporation | Submicron emulsions for delivery of peptides |
US5521284A (en) | 1994-08-01 | 1996-05-28 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide amides and esters |
US5530097A (en) | 1994-08-01 | 1996-06-25 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory peptide amides |
US5504191A (en) | 1994-08-01 | 1996-04-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide methyl esters |
US5554725A (en) | 1994-09-14 | 1996-09-10 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Synthesis of dolastatin 15 |
US5599902A (en) | 1994-11-10 | 1997-02-04 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Cancer inhibitory peptides |
US5663149A (en) | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
JP2000503639A (ja) | 1995-12-22 | 2000-03-28 | ブリストル―マイヤーズ スクイブ カンパニー | 分枝ヒドラゾンのリンカー類 |
CA2282504A1 (en) | 1997-02-25 | 1998-08-27 | Jun-Ping Xu | Isolation and structural elucidation of the cytostatic linear and cyclo-depsipeptides dolastatin 16, dolastatin 17, and dolastatin 18 |
US6323315B1 (en) | 1999-09-10 | 2001-11-27 | Basf Aktiengesellschaft | Dolastatin peptides |
US20020197266A1 (en) | 2000-02-08 | 2002-12-26 | Waldemar Debinski | Immunotherapy using interleukin 13 receptor subunit alpha 2 |
US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
EP1545613B9 (en) | 2002-07-31 | 2012-01-25 | Seattle Genetics, Inc. | Auristatin conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
KR101520209B1 (ko) | 2003-11-06 | 2015-05-13 | 시애틀 지네틱스, 인크. | 리간드에 접합될 수 있는 모노메틸발린 화합물 |
US7691962B2 (en) | 2004-05-19 | 2010-04-06 | Medarex, Inc. | Chemical linkers and conjugates thereof |
US8835608B2 (en) * | 2006-12-01 | 2014-09-16 | Duke University | Anti-MRP3 antibodies and methods of use |
CA2775350A1 (en) | 2009-09-24 | 2011-03-31 | Seattle Genetics, Inc. | Dr5 ligand drug conjugates |
EP2332994A1 (en) * | 2009-12-09 | 2011-06-15 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Trispecific therapeutics against acute myeloid leukaemia |
US20110212088A1 (en) | 2010-02-26 | 2011-09-01 | Sabbadini Roger A | Anti-paf antibodies |
KR102062407B1 (ko) * | 2010-12-09 | 2020-01-03 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 암을 치료하기 위한 키메릭 항원 수용체 변형 t 세포의 용도 |
CA2885761C (en) * | 2012-09-27 | 2021-09-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Mesothelin antibodies and methods for eliciting potent antitumor activity |
US20140186365A1 (en) * | 2013-01-03 | 2014-07-03 | Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center | Antibodies that specifically bind to serum albumin without interfering with albumin's capability to interact with the fcrn |
ES2765710T3 (es) * | 2014-04-03 | 2020-06-10 | Cellectis | Receptores de antígeno quimérico específicos de CD33 para la inmunoterapia del cáncer |
CN112481283A (zh) * | 2014-07-21 | 2021-03-12 | 诺华股份有限公司 | 使用cd33嵌合抗原受体治疗癌症 |
GB201507104D0 (en) * | 2015-04-27 | 2015-06-10 | Ucl Business Plc | Nucleic acid construct |
GB201507368D0 (en) * | 2015-04-30 | 2015-06-17 | Ucl Business Plc | Cell |
AU2016277121C1 (en) * | 2015-06-12 | 2022-07-14 | Lentigen Technology, Inc. | Method to treat cancer with engineered T-cells |
CN104877032B (zh) * | 2015-06-26 | 2018-12-11 | 中国医学科学院血液病医院(血液学研究所) | Cd33特异性嵌合抗原受体及其应用 |
US20180311374A1 (en) * | 2015-10-30 | 2018-11-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv | Targeted cancer therapy |
CN105820255B (zh) * | 2016-04-12 | 2019-06-28 | 上海优卡迪生物医药科技有限公司 | 抗cd33嵌合抗原受体、编码基因、重组表达载体及其构建方法和应用 |
JP7160482B2 (ja) * | 2016-09-02 | 2022-10-25 | レンティジェン・テクノロジー・インコーポレイテッド | Duocarを用いてがんを処置するための組成物および方法 |
JP7137896B2 (ja) | 2017-03-24 | 2022-09-15 | レンティジェン・テクノロジー・インコーポレイテッド | 抗cd33免疫療法によりがんを処置するための組成物および方法 |
-
2018
- 2018-03-23 JP JP2019552109A patent/JP7137896B2/ja active Active
- 2018-03-23 WO PCT/US2018/024183 patent/WO2018175988A1/en active Application Filing
- 2018-03-23 CA CA3057838A patent/CA3057838A1/en active Pending
- 2018-03-23 US US15/934,770 patent/US10426797B2/en active Active
- 2018-03-23 AU AU2018240556A patent/AU2018240556A1/en active Pending
- 2018-03-23 CN CN202011342007.3A patent/CN112695050A/zh active Pending
- 2018-03-23 CN CN201880032715.1A patent/CN110997719B/zh active Active
- 2018-03-23 EP EP18721179.2A patent/EP3601356A1/en active Pending
-
2019
- 2019-09-30 US US16/588,357 patent/US11464801B2/en active Active
-
2022
- 2022-08-18 US US17/820,724 patent/US20230241103A1/en active Pending
- 2022-09-01 JP JP2022139092A patent/JP7448896B2/ja active Active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2020513829A5 (ja) | ||
JP2020533958A5 (ja) | ||
JP2022113880A5 (ja) | ||
JP2020513754A5 (ja) | ||
JP2018515123A5 (ja) | ||
JP2020517295A5 (ja) | ||
JP2019536452A5 (ja) | ||
JP2017524367A5 (ja) | ||
HRP20231542T1 (hr) | Kimerni antigenski receptori koji ciljaju bcma i postupci njihove uporabe | |
JP2020114264A5 (ja) | ||
JP2020525536A5 (ja) | ||
JP2016514462A5 (ja) | ||
JP2019527557A5 (ja) | ||
RU2020100865A (ru) | Лечение рака с помощью гуманизированного анти-cd19 химерного антигенного рецептора | |
JP2017522879A5 (ja) | ||
US11332513B2 (en) | Chimeric antigen receptors having GITR intracellular domain as co-stimulatory domain | |
US20200038443A1 (en) | Multi-function and multi-targeting car system and methods for use thereof | |
JPWO2021102337A5 (ja) | ||
JP2016514457A5 (ja) | ||
JP2017500869A5 (ja) | ||
RU2015117237A (ru) | Химерные антигенные рецепторы м971 | |
JP2021500881A5 (ja) | ||
JP2021502070A5 (ja) | ||
JP2017518071A5 (ja) | ||
JPWO2020018825A5 (ja) |